{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,3,27]],"date-time":"2025-03-27T17:42:42Z","timestamp":1743097362499,"version":"3.37.3"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2022,4,8]],"date-time":"2022-04-08T00:00:00Z","timestamp":1649376000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2022,4,8]],"date-time":"2022-04-08T00:00:00Z","timestamp":1649376000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cardiovasc Drugs Ther"],"published-print":{"date-parts":[[2023,8]]},"DOI":"10.1007\/s10557-022-07332-0","type":"journal-article","created":{"date-parts":[[2022,4,8]],"date-time":"2022-04-08T07:04:17Z","timestamp":1649401457000},"page":"715-727","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Association between Body Mass Index and Clinical Outcomes in Patients with Non-valvular Atrial Fibrillation Receiving Direct Oral Anticoagulants: A New Piece of Evidence on the Obesity Paradox from China"],"prefix":"10.1007","volume":"37","author":[{"given":"Shuyi","family":"Wu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nianxu","family":"Huang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xia","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shaojun","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wang","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wei","family":"Hu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jun","family":"Su","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hengfen","family":"Dai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ping","family":"Gu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaohong","family":"Huang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaoming","family":"Du","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ruijuan","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qiaowei","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiangsheng","family":"Lin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yanxia","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lang","family":"Zou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuxin","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Min","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiumei","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhu","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jianjun","family":"Sun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shanshan","family":"Hong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Weibin","family":"She","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5629-0348","authenticated-orcid":false,"given":"Jinhua","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,4,8]]},"reference":[{"issue":"354","key":"7332_CR1","doi-asserted-by":"publisher","first-page":"i4482","DOI":"10.1136\/bmj.i4482","volume":"6","author":"A Odutayo","year":"2016","unstructured":"Odutayo A, Wong CX, Hsiao AJ, Hopewell S, Altman DG, Emdin CA. Atrial fibrillation and risks of cardiovascular disease, renal disease, and death: systematic review and meta-analysis. BMJ. 2016;6(354):i4482.","journal-title":"BMJ."},{"issue":"8","key":"7332_CR2","doi-asserted-by":"publisher","first-page":"e008150","DOI":"10.1161\/JAHA.117.008150","volume":"7","author":"YH Chan","year":"2018","unstructured":"Chan YH, See LC, Tu HT, Yeh YH, et al. Efficacy and safety of apixaban, dabigatran, rivaroxaban, and warfarin in Asians with nonvalvular atrial fibrillation. J Am Heart Assoc. 2018;7(8):e008150.","journal-title":"J Am Heart Assoc."},{"key":"7332_CR3","doi-asserted-by":"crossref","unstructured":"Aguilar MI, Hart R. Oral anticoagulants for preventing stroke in patients with non-valvular atrial fibrillation and no previous history of stroke or transient ischemic attacks. Cochrane Database Syst Rev. 2005;2005(3):CD001927.","DOI":"10.1002\/14651858.CD001925.pub2"},{"key":"7332_CR4","unstructured":"Camm AJ, Lip GY, De Caterina R, et al.; ESC Committee for Practice Guidelines-CPG. 2012 focused update of the ESC Guidelines for the management of atrial fibrillation: an update of the 2010 ESC Guidelines for the management of atrial fibrillation\u2014developed with the special contribution of the European Heart Rhythm Association. Eur Heart J. 2012;14:1385\u20131413."},{"key":"7332_CR5","doi-asserted-by":"publisher","first-page":"492","DOI":"10.7326\/0003-4819-131-7-199910050-00003","volume":"131","author":"RG Hart","year":"1999","unstructured":"Hart RG, Benavente O, McBride R, et al. Antithrombotic therapy to prevent stroke in patients with atrial fibrillation: a meta-analysis. Ann Intern Med. 1999;131:492\u2013501.","journal-title":"Ann Intern Med."},{"key":"7332_CR6","doi-asserted-by":"publisher","first-page":"e125","DOI":"10.1161\/CIR.0000000000000665","volume":"140","author":"CT January","year":"2019","unstructured":"January CT, Wann LS, Calkins H, et al. 2019 AHA\/ACC\/HRS focused update of the 2014 AHA\/ACC\/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society in Collaboration with the Society of Thoracic Surgeons. Circulation. 2019;140:e125\u201351.","journal-title":"Circulation."},{"key":"7332_CR7","doi-asserted-by":"publisher","first-page":"908","DOI":"10.1111\/bcp.12114","volume":"76","author":"VV Upreti","year":"2013","unstructured":"Upreti VV, Wang J, Barrett YC, et al. Effect of extremes of body weight on the pharmacokinetics, pharmacodynamics, safety and tolerability of apixaban in healthy subjects. Br J Clin Pharmacol. 2013;76:908\u201316.","journal-title":"Br J Clin Pharmacol."},{"key":"7332_CR8","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1177\/0091270006296058","volume":"47","author":"D Kubitza","year":"2007","unstructured":"Kubitza D, Becka M, Zuehlsdorf M, Mueck W. Body weight has limited influence on the safety, tolerability, pharmacokinetics, or pharmacodynamics of rivaroxaban (BAY 59-7939) in healthy subjects. J Clin Pharmacol. 2007;47:218\u201326.","journal-title":"J Clin Pharmacol."},{"issue":"25 Suppl 2","key":"7332_CR9","first-page":"S102","volume":"129","author":"MD Jensen","year":"2014","unstructured":"Jensen MD, Ryan DH, Apovian CM, et al. American College of Cardiology\/American Heart Association Task Force on Practice Guidelines; Obesity Society. 2013 AHA\/ACC\/TOS guideline for the management of overweight and obesity in adults: a report of the American College of Cardiology\/American Heart Association Task Force on Practice Guidelines and The Obesity Society. Circulation. 2014;129(25 Suppl 2):S102\u201338.","journal-title":"Circulation."},{"key":"7332_CR10","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1007\/s00392-017-1102-5","volume":"106","author":"R De Caterina","year":"2017","unstructured":"De Caterina R, GYH L. The non-vitamin K antagonist oral anticoagulants (NOACs) and extremes of body weight-a systematic literature review. Clin Res cardiol: Off J German Cardiac Soc. 2017;106:565\u201372.","journal-title":"Clin Res cardiol: Off J German Cardiac Soc."},{"key":"7332_CR11","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1055\/s-0038-1675816","volume":"119","author":"R De Caterina","year":"2019","unstructured":"De Caterina R, Ageno W, Agnelli G, Chan NC, Diener HC, Hylek E, et al. The non-vitamin K antagonist oral anticoagulants in heart disease: section V-special situations. Thrombosis Haemostasis. 2019;119:14\u201338.","journal-title":"Thrombosis Haemostasis"},{"issue":"2","key":"7332_CR12","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1016\/j.pcad.2018.07.003","volume":"61","author":"A Elagizi","year":"2018","unstructured":"Elagizi A, Kachur S, Lavie CJ, Carbone S, Pandey A, Ortega FB, Milani RV. An overview and update on obesity and the obesity paradox in cardiovascular diseases. Prog Cardiovasc Dis. 2018;61(2):142\u201350.","journal-title":"Prog Cardiovasc Dis."},{"issue":"8","key":"7332_CR13","doi-asserted-by":"publisher","first-page":"970","DOI":"10.1055\/s-0040-1715792","volume":"46","author":"V Russo","year":"2020","unstructured":"Russo V, Bottino R, Rago A, et al. Clinical performance of nonvitamin K antagonist oral anticoagulants in real-world obese patients with atrial fibrillation. Semin Thromb Hemost. 2020 Nov;46(8):970\u20136.","journal-title":"Semin Thromb Hemost."},{"issue":"38","key":"7332_CR14","doi-asserted-by":"publisher","first-page":"2869","DOI":"10.1093\/eurheartj\/ehw124","volume":"37","author":"RK Sandhu","year":"2016","unstructured":"Sandhu RK, Ezekowitz J, Andersson U, et al. The 'obesity paradox' in atrial fibrillation: observations from the ARISTOTLE (Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation) trial. Eur Heart J. 2016;37(38):2869\u201378.","journal-title":"Eur Heart J."},{"issue":"19","key":"7332_CR15","doi-asserted-by":"publisher","first-page":"1541","DOI":"10.1093\/eurheartj\/ehy861","volume":"40","author":"G Boriani","year":"2019","unstructured":"Boriani G, Ruff CT, Kuder JF, et al. Relationship between body mass index and outcomes in patients with atrial fibrillation treated with edoxaban or warfarin in the ENGAGE AF-TIMI 48 trial. Eur Heart J. 2019;40(19):1541\u201350.","journal-title":"Eur Heart J."},{"issue":"1","key":"7332_CR16","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1016\/j.amjcard.2016.04.013","volume":"118","author":"M Proietti","year":"2016","unstructured":"Proietti M, Lane DA, Lip GY. Relation of nonvalvular atrial fibrillation to body mass index (from the SPORTIF Trials). Am J Cardiol. 2016;118(1):72\u20138.","journal-title":"Am J Cardiol."},{"issue":"12","key":"7332_CR17","doi-asserted-by":"publisher","first-page":"1989","DOI":"10.1016\/j.amjcard.2017.03.028","volume":"119","author":"SR Balla","year":"2017","unstructured":"Balla SR, Cyr DD, Lokhnygina Y, et al. Relation of risk of stroke in patients with atrial fibrillation to body mass index (from patients treated with rivaroxaban and warfarin in the Rivaroxaban Once Daily Oral Direct Factor Xa Inhibition Compared with Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation Trial). Am J Cardiol. 2017;119(12):1989\u201396.","journal-title":"Am J Cardiol."},{"key":"7332_CR18","first-page":"333","volume":"2","author":"D Rao","year":"2018","unstructured":"Rao D, Tolu SS, Choi Y, Gao J, Billett HH, Kushnir M. Efficacy and safety of rivaroxaban in morbid obesity: a retrospective analysis of over 600 patients with BMI \u2265 40. Res Pract Thromb Haemost. 2018;2:333\u20134.","journal-title":"Res Pract Thromb Haemost."},{"issue":"228","key":"7332_CR19","doi-asserted-by":"publisher","first-page":"771","DOI":"10.1016\/j.ijcard.2016.11.277","volume":"1","author":"CH Lee","year":"2017","unstructured":"Lee CH, Lin TY, Chang SH, et al. Body mass index is an independent predictor of major bleeding in non-valvular atrial fibrillation patients taking dabigatran. Int J Cardiol. 2017;1(228):771\u20138.","journal-title":"Int J Cardiol."},{"issue":"4","key":"7332_CR20","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1016\/j.hrthm.2016.12.036","volume":"14","author":"CS Park","year":"2017","unstructured":"Park CS, Choi EK, Kim HM, Lee SR, Cha MJ, Oh S. Increased risk of major bleeding in underweight patients with atrial fibrillation who were prescribed non-vitamin K antagonist oral anticoagulants. Heart Rhythm. 2017;14(4):501\u20137.","journal-title":"Heart Rhythm."},{"issue":"2","key":"7332_CR21","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1161\/STROKEAHA.120.030356","volume":"52","author":"SR Lee","year":"2021","unstructured":"Lee SR, Choi EK, Jung JH, Park SH, Han KD, Oh S, GYH L. Body mass index and clinical outcomes in Asian patients with atrial fibrillation receiving oral anticoagulation. Stroke. 2021;52(2):521\u201330.","journal-title":"Stroke."},{"key":"7332_CR22","doi-asserted-by":"crossref","unstructured":"Bottino R, Carbone A, Liccardo B, et al. The \u201cObesity Paradox\u201d and the use of NOAC. Direct Oral Anticoagulants. 2021;149\u201378.","DOI":"10.1007\/978-3-030-74462-5_9"},{"issue":"9403","key":"7332_CR23","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1016\/S0140-6736(03)15268-3","volume":"363","author":"WHO Expert Consultation","year":"2004","unstructured":"WHO Expert Consultation. Appropriate body-mass index for Asian populations and its implications for policy and intervention strategies. Lancet. 2004;363(9403):157\u201363.","journal-title":"Lancet."},{"issue":"2","key":"7332_CR24","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1378\/chest.09-1584","volume":"137","author":"GY Lip","year":"2010","unstructured":"Lip GY, Nieuwlaat R, Pisters R, Lane DA, Crijns HJ. Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the euro heart survey on atrial fibrillation. Chest. 2010;137(2):263\u201372.","journal-title":"Chest."},{"issue":"5","key":"7332_CR25","doi-asserted-by":"publisher","first-page":"1093","DOI":"10.1378\/chest.10-0134","volume":"138","author":"R Pisters","year":"2010","unstructured":"Pisters R, Lane DA, Nieuwlaat R, de Vos CB, Crijns HJ, Lip GY. A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: the Euro Heart Survey. Chest. 2010;138(5):1093\u2013100.","journal-title":"Chest."},{"key":"7332_CR26","doi-asserted-by":"publisher","first-page":"692","DOI":"10.1111\/j.1538-7836.2005.01204.x","volume":"3","author":"S Schulman","year":"2005","unstructured":"Schulman S, Kearon C. Subcommittee on Control of Anticoagulation of the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis. Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients. J Thromb Haemost. 2005;3:692\u20134.","journal-title":"J Thromb Haemost"},{"issue":"12","key":"7332_CR27","doi-asserted-by":"publisher","first-page":"1139","DOI":"10.1056\/NEJMoa0905561","volume":"361","author":"SJ Connolly","year":"2009","unstructured":"Connolly SJ, Ezekowitz MD, Yusuf S, et al. RE-LY Steering Committee and Investigators. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med. 2009;361(12):1139\u201351.","journal-title":"N Engl J Med."},{"issue":"301","key":"7332_CR28","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1016\/j.ijcard.2019.10.035","volume":"15","author":"M Lucijanic","year":"2020","unstructured":"Lucijanic M, Jurin I, Jurin H, et al. Patients with higher body mass index treated with direct\/novel oral anticoagulants (DOAC \/ NOAC) for atrial fibrillation experience worse clinical outcomes. Int J Cardiol. 2020;15(301):90\u20135.","journal-title":"Int J Cardiol."},{"issue":"2","key":"7332_CR29","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1177\/1060028018796604","volume":"53","author":"K Kido","year":"2019","unstructured":"Kido K, Ngorsuraches S. Comparing the efficacy and safety of direct oral anticoagulants with warfarin in the morbidly obese population with atrial fibrillation. Ann Pharmacother. 2019;53(2):165\u201370.","journal-title":"Ann Pharmacother."},{"issue":"4","key":"7332_CR30","doi-asserted-by":"publisher","first-page":"494","DOI":"10.1038\/ejcn.2016.183","volume":"71","author":"H Wan","year":"2017","unstructured":"Wan H, Wu S, Wang J, et al. Body mass index and the risk of all-cause mortality among patients with non-valvular atrial fibrillation: a multicenter prospective observational study in China. Eur J Clin Nutr. 2017;71(4):494\u20139.","journal-title":"Eur J Clin Nutr."}],"container-title":["Cardiovascular Drugs and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10557-022-07332-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10557-022-07332-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10557-022-07332-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,2]],"date-time":"2023-08-02T10:15:35Z","timestamp":1690971335000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10557-022-07332-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,4,8]]},"references-count":30,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2023,8]]}},"alternative-id":["7332"],"URL":"https:\/\/doi.org\/10.1007\/s10557-022-07332-0","relation":{},"ISSN":["0920-3206","1573-7241"],"issn-type":[{"type":"print","value":"0920-3206"},{"type":"electronic","value":"1573-7241"}],"subject":[],"published":{"date-parts":[[2022,4,8]]},"assertion":[{"value":"1 March 2022","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 April 2022","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study complies with the Declaration of Helsinki and was authorized by The Ethics Committee of Fujian Medical University Union Hospital.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}},{"value":"The requirement for patient consent was waived due to its retrospective nature.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed Consent"}},{"value":"The authors declare that they have no conflicts of interest.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}}]}}